dual CD33-CLL1 CAR-T cells

Dual CD33-CLL1 CAR-T cells are a form of chimeric antigen receptor T cell therapy engineered to target both the Myeloid cell surface antigen CD33 and C-type lectin domain family 12 member A (CLL1/CLEC12A) antigens on acute myeloid leukemia (AML) cells. This dual-targeting approach is designed to enhance anti-leukemic efficacy by addressing tumor heterogeneity and reducing the risk of relapse due to antigen escape. Preclinical and early clinical studies have shown that these tandem or compound CAR-T constructs exhibit potent cytotoxicity against AML blasts while sparing normal hematopoietic stem cells, resulting in effective tumor eradication with manageable toxicity profiles. The therapy has demonstrated promising results in relapsed/refractory AML patients—including pediatric populations—with high rates of complete remission and measurable residual disease negativity. Dual targeting may also serve as an effective conditioning regimen prior to hematopoietic stem cell transplantation[1][3][5][6].

Other names

tandem CD33-CLL1 CAR-Tmulti-specific CD33-CLL1 CAR-T